Yonina Murciano-Goroff
@yoninamg
Opinions are my own.
ID: 1249775659934789633
13-04-2020 19:05:17
42 Tweet
190 Followers
294 Following
#Genetics has become an integral part of #cancercare. Dr. Zsofia K. Stadler & Kelsey Breen invite you to the Hereditary Cancer Genetics course Memorial Sloan Kettering Cancer Center featuring expert faculty in #hereditarycancer syndromes: vimeo.com/730372325 Register at: bit.ly/HereditaryCanc…
In a News and Views now published online, Yonina R. Murciano-Goroff and Piro Lito Memorial Sloan Kettering Cancer Center discuss results from the KRYSTAL-1 trial of adagrasib in #lungcancer, putting them in context with the currently available data on sotorasib nature.com/articles/s4157…
New! Although positive germline findings are prevalent in diverse, pan-cancer patients, Black patients are less likely to get recommended genetics care compared to White patients—and this disparity could affect cancer outcomes and families. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… CC: OncoAlert
Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to Noura Choudhury, MD Yonina Murciano-Goroff Neil Vasan and the many contributing authors!! amazon.com/gp/aw/d/B0B9T5…
Excited to share work done with many collaborators Memorial Sloan Kettering Cancer Center and showing that ctDNA testing expands access to life-prolonging therapy for patients with lung cancer! Memorial Sloan Kettering Radiation Oncology nature.com/articles/s4159…
Huge thanks and Kudos to all the authors and collaborators Rona Yaeger Rosenlab Lowe Lab riccardo.mezzadra David B. Solit, MD Michael Berger Yonina Murciano-Goroff Ria Boundless Bio 💪💪💪and Cancer Discovery and Michele Hartsough for the amazing work together! Ad Maiora!
Our work on BRCA1/2 reversion mutations in a pan-cancer cohort reveals a BRCA-mediated phenotype in non-canonical histologies. Kudos to a great team! Alexander Drilon MD Chai Bandlamudi Alison Schram Yelena Y. Janjigian MD Zsofia Stadler Michael Berger nature.com/articles/s4146…
Fantastic collaboration with Yonina Murciano-Goroff, Alexander Drilon MD, Michael Berger, Zsofia Stadler and MSKCC Center for Molecular Oncology (CMO). We analyze our #MSKIMPACT clinical sequencing cohort for evidence of germline BRCA1/2 mediated tumorigenesis in non-BRCA-associated cancers. 1/5
RT: Featured today by MSK Library: Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies dx.doi.org/10.1038/s41467…
Drs. Yonina Murciano-Goroff Alexander Drilon MD and team report on CNS disease in #RET fusion-positive NSCLC with selpercatinib JTO & JTO CRR. In pts with CNS metastases, only 20% with CNS progression at 3y. In pts without brain metastases, 0% (!) had CNS metastases at 3y. #LCSM jto.org/article/S1556-…
Today at #AACR23, Yonina Murciano-Goroff will present results of a first-in-human phase 1 study of LY3537982 — a highly selective #KRAS G12C inhibitor in people with advanced solid tumors with this mutation — at 2:35 in the Chaplin Theater. bit.ly/43y41Rn
Dr. Yonina Murciano-Goroff (Yonina Murciano-Goroff) studies early drug development for #cancer. At #AACR23, she shared new research into how she's using biomarkers and genomic data from MSK-IMPACT® to identify effective treatments for patients.
At #ESMO25, join Yonina Murciano-Goroff to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. Memorial Sloan Kettering Cancer Center ESMO - Eur. Oncology Learn more: bit.ly/4nafnUa
